 <h1>Bosutinib Side Effects</h1><ul class="ddc-anchor-links"><li>Consumer</li>
<li>Professional</li></ul><h2>In Summary</h2><p><b>Commonly reported side effects of bosutinib include:</b> diarrhea, abdominal pain, anemia, edema, increased serum alanine aminotransferase, increased serum aspartate aminotransferase, nausea, neutropenia, peripheral edema, thrombocytopenia, and vomiting.  See below for a comprehensive list of adverse effects.</p><h2 class="ddc-anchor-offset" id="consumer">For the Consumer</h2><p><i>Applies to bosutinib: oral tablet</i></p><h3>Side effects requiring immediate medical attention</h3><p>Along with its needed effects, bosutinib may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.</p><p>
<b>Check with your doctor immediately</b> if any of the following side effects occur while taking bosutinib:</p><p>
<i>More common</i>
</p><ul>
<li>Black, tarry stools</li>
<li>bleeding gums</li>
<li>blood in the urine or stools</li>
<li>chills</li>
<li>cough</li>
<li>difficult or labored breathing</li>
<li>fever</li>
<li>lower back or side pain</li>
<li>painful or difficult urination</li>
<li>pale skin</li>
<li>pinpoint red spots on the skin</li>
<li>sore throat</li>
<li>swelling of the hands, ankles, feet, or lower legs</li>
<li>tightness in the chest</li>
<li>troubled breathing with exertion</li>
<li>ulcers, sores, or white spots in the mouth</li>
<li>unusual bleeding or bruising</li>
<li>unusual tiredness or weakness</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Agitation</li>
<li>chest pain or discomfort</li>
<li>clay-colored stools</li>
<li>cough with mucus</li>
<li>confusion</li>
<li>dark urine</li>
<li>decreased appetite</li>
<li>decreased urination</li>
<li>depression</li>
<li>diarrhea</li>
<li>dizziness</li>
<li>dry mouth</li>
<li>fainting</li>
<li>fast or irregular heartbeat</li>
<li>general feeling of discomfort or illness</li>
<li>headache</li>
<li>hives, itching, or skin rash</li>
<li>hoarseness</li>
<li>hostility</li>
<li>increased sweating</li>
<li>increased thirst</li>
<li>irritation</li>
<li>joint pain, stiffness or swelling</li>
<li>lightheadedness</li>
<li>loss of appetite</li>
<li>muscle aches, pains, or twitching</li>
<li>nausea</li>
<li>numbness or tingling in the hands, feet, or lips</li>
<li>rapid breathing</li>
<li>rapid weight gain</li>
<li>redness of the skin</li>
<li>runny nose</li>
<li>seizures</li>
<li>shivering</li>
<li>sneezing</li>
<li>stomach pain or tenderness</li>
<li>sunken eyes</li>
<li>swelling of the eyelids, face, lips, hands, or feet</li>
<li>thirst</li>
<li>trouble sleeping</li>
<li>trouble swallowing</li>
<li>vomiting</li>
<li>weakness or heaviness of the legs</li>
<li>wrinkled skin</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Blistering, peeling, or loosening of the skin</li>
<li>bloating</li>
<li>blue lips, fingernails, or skin</li>
<li>chest pain, possibly moving to the left arm, neck, or shoulder</li>
<li>constipation</li>
<li>coughing that sometimes produces a pink frothy sputum</li>
<li>difficult, noisy breathing</li>
<li>indigestion</li>
<li>irregular, fast or slow, or shallow breathing</li>
<li>pains in the stomach, side, or abdomen, possibly radiating to the back</li>
<li>puffiness or swelling of the eyelids or around the eyes, face, lips or tongue</li>
<li>red, irritated eyes</li>
<li>vomiting of blood or material that looks like coffee grounds</li>
<li>yellow eyes or skin</li>
</ul><h3>Side effects not requiring immediate medical attention</h3><p>Some side effects of bosutinib may occur that usually <b>do not need medical attention</b>. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.</p><p>Check with your health care professional if any of the following side effects <b>continue or are bothersome</b> or if you have any questions about them:</p><p>
<i>More common</i>
</p><ul>
<li>Back pain</li>
<li>difficulty with moving</li>
<li>lack or loss of strength</li>
<li>muscle stiffness</li>
<li>stuffy nose</li>
</ul><p>
<i>Less common</i>
</p><ul>
<li>Blemishes on the skin</li>
<li>burning feeling in the chest or stomach</li>
<li>change in taste</li>
<li>hearing loss</li>
<li>loss of taste</li>
<li>muscle cramping</li>
<li>pimples</li>
<li>ringing, buzzing, or other unexplained noise in the ears that continues</li>
<li>stomach upset</li>
</ul><p>
<i>Rare</i>
</p><ul>
<li>Flaking and falling off of the skin</li>
</ul><p>
<!-- end oral tablet --><div class="related-links"><svg aria-hidden="true" class="ddc-icon ddc-icon-info" focusable="false" height="22" viewbox="0 0 24 24" width="22" xmlns="http://www.w3.org/2000/svg"><path d="M14 2H6c-1.1 0-1.99.9-1.99 2L4 20c0 1.1.89 2 1.99 2H18c1.1 0 2-.9 2-2V8l-6-6zm2 16H8v-2h8v2zm0-4H8v-2h8v2zm-3-5V3.5L18.5 9H13z"></path></svg> <span>Managing side effects <span class="ddc-text-nowrap">(general information)</span></span></div>
<h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to bosutinib: oral tablet</i></p><h3>General</h3><p>The most commonly reported side effects were diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Pericardial effusion, chest pain, prolonged QT interval</p>
<p><b>Uncommon</b> (0.1% to 1%): Pericarditis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Low platelet count (less than 50 × 10(9)/L, up to 57%), thrombocytopenia (up to 40%), absolute neutrophil count (less than 1 × 10(9)/L, up to 37%), Low hemoglobin (less than 80 g/L, up to 35%), anemia (up to 27%), neutropenia (16%), leukopenia (11%)</p>
<p><b>Common</b> (1% to 10%): Febrile neutropenia</p>
<p><b>Uncommon</b> (0.1% to 1%): Granulocytopenia</p>
<p><b>Frequency not reported</b>: Myelosuppression<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased alanine aminotransferase (up to 22%), increased aspartate aminotransferase (up to 18%)</p>
<p><b>Common</b> (1% to 10%): Increased bilirubin [greater than 3 times the upper limit of normal (3 x ULN)], hepatotoxicity, abnormal hepatic function, increased gamma-glutamyltransferase</p>
<p><b>Uncommon</b> (0.1% to 1%): Liver injury</p>
<p><b>Frequency not reported</b>: Hepatic toxicity<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 84%), nausea (up to 46%), abdominal pain (up to 40%), vomiting (up to 37%)</p>
<p><b>Common</b> (1% to 10%): Increased lipase (greater than 2 × ULN), gastritis, increased blood amylase</p>
<p><b>Uncommon</b> (0.1% to 1%): Acute pancreatitis, gastrointestinal hemorrhage</p>
<p><b>Frequency not reported</b>: Gastrointestinal toxicity<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (up to 34%), pruritus (up to 11%)</p>
<p><b>Common</b> (1% to 10%): Urticaria, pruritus, acne</p>
<p><b>Uncommon</b> (0.1% to 1%): Erythema multiforme, exfoliative rash, drug eruption<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Drug hypersensitivity</p>
<p><b>Uncommon</b> (0.1% to 1%): Anaphylactic shock<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (up to 20%), nasopharyngitis (up to 12%), respiratory tract infection (up to 12%), dyspnea (up to 10%)</p>
<p><b>Common</b> (1% to 10%): Pneumonia, influenza, bronchitis, pleural effusion</p>
<p><b>Uncommon</b> (0.1% to 1%): Acute pulmonary edema, respiratory failure, pulmonary hypertension<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (up to 13%)</p>
<p><b>Common</b> (1% to 10%): Hyperkalemia, dehydration</p>
<p><b>Frequency not reported</b>: Fluid retention<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (up to 14%), back pain (up to 12%)</p>
<p><b>Common</b> (1% to 10%): Myalgia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 20%), dizziness (up to 10%)</p>
<p><b>Common</b> (1% to 10%): Dysgeusia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (up to 26%), pyrexia (up to 22%), edema (up to 14%), asthenia (11%)</p>
<p><b>Common</b> (1% to 10%): Low phosphorus (less than 0.6 mmol/L), tinnitus, pain, increased blood creatine phosphokinase<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Increased blood creatinine</p>
<p><b>Uncommon</b> (0.1% to 1%): Acute renal failure, renal failure, renal impairment<sup>[Ref]</sup></p><div class="referenceList"><h4 id="refs">References</h4><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Bosulif (bosutinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY. </p></div>
<div class="more-resources" id="moreResources">
<h2>More about bosutinib</h2>
<ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>5 Reviews</li>
<li>Drug class: BCR-ABL tyrosine kinase inhibitors</li>
</ul>
<h3>Consumer resources</h3>
<ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Bosutinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul>
<dl class="more-resources-other-brands more-resources-other-brands-consumer"><dt>Other brands</dt><dd>Bosulif</dd></dl>
<h3>Professional resources</h3>
<ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul>
<h3>Related treatment guides</h3>
<ul class="more-resources-list more-resources-list-conditions">
<li>Chronic Myelogenous Leukemia</li>
</ul>
</div>
<h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p>
<p>Some side effects may not be reported. You may report them to the FDA.</p>
<p class="ddc-disclaimer-link">Medical Disclaimer</p>
<script>
function showRefs(refs) {
	if (!document.querySelectorAll) {
		return;
	}

	var referenceIds = refs ? refs.split(',') : [];
	var referenceTitle = referenceIds.length
		 ? "References relevant to chosen section <span class='ddc-text-size-small font-weight-normal'>(<a href='#refs' onclick='showRefs(\"\"); return false;'>Show all references</a>)</span>"
		 : "References";
	document.getElementById('refs').innerHTML = referenceTitle;

	// Show/hide reference items
	var referenceList = document.querySelectorAll('.referenceList p');
	referenceList.forEach(function(item) {
		var id = item.id.replace('ref_', '');
		if (!referenceIds.length || referenceIds.includes(id)) {
			item.style.display = 'block';
		}
		else {
			item.style.display = 'none';
		}
	});
}
</script>
</p><h2 class="ddc-anchor-offset" id="professional">For Healthcare Professionals</h2><p><i>Applies to bosutinib: oral tablet</i></p><h3>General</h3><p>The most commonly reported side effects were diarrhea, nausea, thrombocytopenia, vomiting, abdominal pain, rash, anemia, pyrexia, and fatigue.<sup>[Ref]</sup></p><h3>Cardiovascular</h3><p><b>Common</b> (1% to 10%): Pericardial effusion, chest pain, prolonged QT interval</p><p><b>Uncommon</b> (0.1% to 1%): Pericarditis<sup>[Ref]</sup></p><h3>Hematologic</h3><p><b>Very common</b> (10% or more): Low platelet count (less than 50 × 10(9)/L, up to 57%), thrombocytopenia (up to 40%), absolute neutrophil count (less than 1 × 10(9)/L, up to 37%), Low hemoglobin (less than 80 g/L, up to 35%), anemia (up to 27%), neutropenia (16%), leukopenia (11%)</p><p><b>Common</b> (1% to 10%): Febrile neutropenia</p><p><b>Uncommon</b> (0.1% to 1%): Granulocytopenia</p><p><b>Frequency not reported</b>: Myelosuppression<sup>[Ref]</sup></p><h3>Hepatic</h3><p><b>Very common</b> (10% or more): Increased alanine aminotransferase (up to 22%), increased aspartate aminotransferase (up to 18%)</p><p><b>Common</b> (1% to 10%): Increased bilirubin [greater than 3 times the upper limit of normal (3 x ULN)], hepatotoxicity, abnormal hepatic function, increased gamma-glutamyltransferase</p><p><b>Uncommon</b> (0.1% to 1%): Liver injury</p><p><b>Frequency not reported</b>: Hepatic toxicity<sup>[Ref]</sup></p><h3>Gastrointestinal</h3><p><b>Very common</b> (10% or more): Diarrhea (up to 84%), nausea (up to 46%), abdominal pain (up to 40%), vomiting (up to 37%)</p><p><b>Common</b> (1% to 10%): Increased lipase (greater than 2 × ULN), gastritis, increased blood amylase</p><p><b>Uncommon</b> (0.1% to 1%): Acute pancreatitis, gastrointestinal hemorrhage</p><p><b>Frequency not reported</b>: Gastrointestinal toxicity<sup>[Ref]</sup></p><h3>Dermatologic</h3><p><b>Very common</b> (10% or more): Rash (up to 34%), pruritus (up to 11%)</p><p><b>Common</b> (1% to 10%): Urticaria, pruritus, acne</p><p><b>Uncommon</b> (0.1% to 1%): Erythema multiforme, exfoliative rash, drug eruption<sup>[Ref]</sup></p><h3>Hypersensitivity</h3><p><b>Common</b> (1% to 10%): Drug hypersensitivity</p><p><b>Uncommon</b> (0.1% to 1%): Anaphylactic shock<sup>[Ref]</sup></p><h3>Respiratory</h3><p><b>Very common</b> (10% or more): Cough (up to 20%), nasopharyngitis (up to 12%), respiratory tract infection (up to 12%), dyspnea (up to 10%)</p><p><b>Common</b> (1% to 10%): Pneumonia, influenza, bronchitis, pleural effusion</p><p><b>Uncommon</b> (0.1% to 1%): Acute pulmonary edema, respiratory failure, pulmonary hypertension<sup>[Ref]</sup></p><h3>Metabolic</h3><p><b>Very common</b> (10% or more): Decreased appetite (up to 13%)</p><p><b>Common</b> (1% to 10%): Hyperkalemia, dehydration</p><p><b>Frequency not reported</b>: Fluid retention<sup>[Ref]</sup></p><h3>Musculoskeletal</h3><p><b>Very common</b> (10% or more): Arthralgia (up to 14%), back pain (up to 12%)</p><p><b>Common</b> (1% to 10%): Myalgia<sup>[Ref]</sup></p><h3>Nervous system</h3><p><b>Very common</b> (10% or more): Headache (up to 20%), dizziness (up to 10%)</p><p><b>Common</b> (1% to 10%): Dysgeusia<sup>[Ref]</sup></p><h3>Other</h3><p><b>Very common</b> (10% or more): Fatigue (up to 26%), pyrexia (up to 22%), edema (up to 14%), asthenia (11%)</p><p><b>Common</b> (1% to 10%): Low phosphorus (less than 0.6 mmol/L), tinnitus, pain, increased blood creatine phosphokinase<sup>[Ref]</sup></p><h3>Renal</h3><p><b>Common</b> (1% to 10%): Increased blood creatinine</p><p><b>Uncommon</b> (0.1% to 1%): Acute renal failure, renal failure, renal impairment<sup>[Ref]</sup></p><p id="ref_1">1. Cerner Multum,  Inc. "UK Summary of Product Characteristics." O 0</p><p id="ref_2">2. "Product Information. Bosulif (bosutinib)." Pfizer U.S. Pharmaceuticals Group, New York, NY. </p><h2>More about bosutinib</h2><ul class="more-resources-list more-resources-list-general">
<li>During Pregnancy or 
Breastfeeding</li>
<li>Dosage Information</li>
<li>Drug Interactions</li>
<li>En Español</li>
<li>5 Reviews</li>
<li>Drug class: BCR-ABL tyrosine kinase inhibitors</li>
</ul><h3>Consumer resources</h3><ul class="more-resources-list more-resources-list-consumer">
<li>Patient Information</li>
<li>Bosutinib &lt;span&gt;(Advanced Reading)&lt;/span&gt;</li>
</ul><h3>Professional resources</h3><ul class="more-resources-list more-resources-list-professional">
<li>Prescribing Information</li>
<li data-more-config-id="list-data-resources-professional">... +1 more</li>
</ul><h3>Related treatment guides</h3><ul class="more-resources-list more-resources-list-conditions">
<li>Chronic Myelogenous Leukemia</li>
</ul><h2>Further information</h2><p class="ddc-disclaimer">Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.</p><p>Some side effects may not be reported. You may report them to the FDA.</p><p class="ddc-disclaimer-link">Medical Disclaimer</p>